MedTrace Logo

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

NCT04129216 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-05-07

Study results available
· View outcomes & findings →

Summary

The investigators would like to study the genetic and molecular outcomes that results after a short term neoadjuvant hormonal therapy on patients with breast cancer.

Conditions

Interventions

DRUG

Tamoxifen Citrate

10mg administered daily. Patients take this drug for 2-6 weeks

DRUG

Letrozole

2.5mg is administered daily. Patients take this drug for 2-6 weeks

DRUG

Exemestane

25mg is administered daily. Patients take this drug for 2-6 weeks.

DIAGNOSTIC_TEST

Blueprint

studies the genomics of the tumor and tumor behavior

DIAGNOSTIC_TEST

Mammaprint

studies the genomics of the tumor

Sponsors & Collaborators

Principal Investigators

  • Mehran Habibi, MD · Johns Hopkins Bayview

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-20
Primary Completion
2022-11-10
Completion
2022-11-10
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04129216 on ClinicalTrials.gov